Breast Cancer Recurrence Treated With Radiation Despite a Chronic Skin Condition

This breast cancer diagnosis at a glance

Subtype
Invasive Ductal Carcinoma
Biomarkers
ER-positive; PR-positive; HER2-negative
Sex
Female
Treatment
surgery, hormone therapy and radiation
Outcome
Care Ongoing

Treatment course, step by step

  1. Right mastectomy and axillary node clearance in March 2015, with 1 of 16 nodes positive.
  2. Anastrozole hormone therapy.
  3. Resection of chest-wall recurrence in August 2019, with tumour at the deep margin.
  4. Stereotactic ablative radiotherapy to a suspicious left ischial lesion in three fractions.
  5. Hormone therapy changed from anastrozole to exemestane.
  6. Chest-wall radiotherapy in February 2020, 50.4 Gy in 28 fractions over 5.5 weeks.
  7. Adjuvant chemotherapy was declined.

What happened, in summary

A 56-year-old woman was diagnosed in February 2015 with multifocal right breast cancer. Pathology showed two grade 2 invasive ductal carcinomas measuring 48 mm and 12 mm, with lymphovascular invasion. The tumours were oestrogen- and progesterone-receptor positive and HER2 negative. She also had longstanding hidradenitis suppurativa affecting her axillae and groins, which complicated wound care. In March 2015, she underwent mastectomy and axillary node clearance; 1 of 16 lymph nodes contained cancer. The surgical wound opened and healed slowly, with malodour and infection requiring antibiotics, antiseptic soaks, and topical treatment. She declined adjuvant chemotherapy, and radiation was deferred because healing continued for 8 months. She started anastrozole. In July 2019, a mass near the mastectomy scar was biopsied and confirmed recurrent breast cancer. It was removed the next month, but tumour remained at the deep margin. Imaging also found a suspicious, FDG-avid lesion in the left ischium, which was treated with stereotactic ablative radiotherapy in three fractions. Endocrine therapy was changed to exemestane. Because of the positive chest-wall margin and high local-recurrence risk, she received 50.4 Gy of chest-wall radiation in 28 daily fractions over 5.5 weeks in February 2020. She developed areas of moist skin peeling, but her hidradenitis did not flare. The irradiated skin healed completely within 5 weeks, and she continued multidisciplinary follow-up.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar breast cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more breast cancer stories